Transgene

Transgene EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Transgene (TNG.PA) as of Oct 13, 2026 is -84.54 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -66.37 % — a change of 27.37% (lower).

EBIT/Assets

-84.54 %

YoY

27.37%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Transgene is 2024 -84.54 % . Operating Income to Assets Ratio (EBIT/Assets) of Transgene was 2023 -66.37 % . It decreases by 27.37% lower compared to the previous year.

The Transgene EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2017
-27.74 EUR
Jan 1, 2018
6.80 EUR
Jan 1, 2019
-21.99 EUR
Jan 1, 2020
-28.08 EUR
Jan 1, 2021
-23.10 EUR
Jan 1, 2022
-45.00 EUR
Jan 1, 2023
-66.37 EUR
Jan 1, 2024
-84.54 EUR
The Transgene EBIT/Assets history
YEAREBIT/AssetsYoY
-84.54 %+27.37%
-66.37 %+47.49%
-45.00 %+94.85%
-23.10 %-17.74%
-28.08 %+27.67%
-21.99 %-423.40%
6.80 %-124.51%
-27.74 %+52.14%
-18.24 %-34.91%
-28.02 %+14.67%
-24.43 %—
Access this data via the Eulerpool API

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Operating Income to Assets Ratio (EBIT/Assets) of Transgene is -84.54 % in 2024.

Operating Income to Assets Ratio (EBIT/Assets) of Transgene changed from -66.37 % to -84.54 %, representing a 27.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Transgene since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Transgene with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

Profitability — Transgene

All Key Metrics — Transgene